FindTrial
Sign In

Long-term study of HP-3000 in patients with Parkinson's disease

A phase III long-term study of HP-3000 in patients with Parkinson's disease

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222696
Enrollment
Unknown
Registered
2014-12-16
Start date
2014-12-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

investigational material(s) Generic name etc : HP-3000(ropinirole hydrochloride patch) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administrat

Sponsors

Hisamitsu Pharmaceutical Co.,Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with Parkinson's disease in stages 1 to 4 on the modified Hoehn & Yahr scale.

Exclusion criteria

Exclusion criteria: - Patients with history of hypersensitivity to ropinirole. - Patients with severe hepatic dysfunction. - Patients who have cutaneous abnormality at planned application site that can be worsen by application with investigational product.

Design outcomes

Primary

MeasureTime frame
Safety, and efficacy.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026